MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - pharmaceuticals
- TORRENT PHARMA - IPCA LABS
TORRENT PHARMA vs IPCA LABS - Comparison Results
TORRENT PHARMA Change
Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More
IPCA LABS 
Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More
Current Valuations
| TORRENT PHARMA | IPCA LABS | TORRENT PHARMA/ IPCA LABS |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 35.1 | 21.7 | 161.6% | View Chart |
| P/BV | x | 8.9 | 7.8 | 114.4% | View Chart |
| Dividend Yield | % | 0.7 | 0.2 | 439.3% |
Financials
 TORRENT PHARMA  IPCA LABS |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| TORRENT PHARMA Mar-19 |
IPCA LABS Mar-19 |
TORRENT PHARMA/ IPCA LABS |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 1,964 | 1,042 | 188.5% | |
| Low | Rs | 1,245 | 590 | 211.0% | |
| Sales per share (Unadj.) | Rs | 453.4 | 298.6 | 151.8% | |
| Earnings per share (Unadj.) | Rs | 25.8 | 35.0 | 73.7% | |
| Cash flow per share (Unadj.) | Rs | 62.3 | 49.4 | 126.0% | |
| Dividends per share (Unadj.) | Rs | 17.00 | 3.00 | 566.7% | |
| Dividend yield (eoy) | % | 1.1 | 0.4 | 288.2% | |
| Book value per share (Unadj.) | Rs | 279.2 | 247.1 | 113.0% | |
| Shares outstanding (eoy) | m | 169.22 | 126.35 | 133.9% | |
| Bonus/Rights/Conversions | - | ESOS | - | ||
| Price / Sales ratio | x | 3.5 | 2.7 | 129.5% | |
| Avg P/E ratio | x | 62.2 | 23.3 | 266.9% | |
| P/CF ratio (eoy) | x | 25.8 | 16.5 | 156.1% | |
| Price / Book Value ratio | x | 5.7 | 3.3 | 174.0% | |
| Dividend payout | % | 65.9 | 8.6 | 769.2% | |
| Avg Mkt Cap | Rs m | 271,513 | 103,108 | 263.3% | |
| No. of employees | `000 | 13.6 | 13.4 | 101.2% | |
| Total wages/salary | Rs m | 14,038 | 7,874 | 178.3% | |
| Avg. sales/employee | Rs Th | 5,642.6 | 2,807.0 | 201.0% | |
| Avg. wages/employee | Rs Th | 1,032.4 | 585.8 | 176.2% | |
| Avg. net profit/employee | Rs Th | 320.9 | 329.0 | 97.5% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 76,728 | 37,732 | 203.4% | |
| Other income | Rs m | 571 | 577 | 98.9% | |
| Total revenues | Rs m | 77,299 | 38,309 | 201.8% | |
| Gross profit | Rs m | 19,831 | 6,901 | 287.4% | |
| Depreciation | Rs m | 6,177 | 1,824 | 338.6% | |
| Interest | Rs m | 5,038 | 189 | 2,669.6% | |
| Profit before tax | Rs m | 9,187 | 5,465 | 168.1% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | -3,570 | 0 | - | |
| Tax | Rs m | 1,254 | 1,042 | 120.3% | |
| Profit after tax | Rs m | 4,363 | 4,422 | 98.7% | |
| Gross profit margin | % | 25.8 | 18.3 | 141.3% | |
| Effective tax rate | % | 13.6 | 19.1 | 71.5% | |
| Net profit margin | % | 5.7 | 11.7 | 48.5% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 50,375 | 23,778 | 211.9% | |
| Current liabilities | Rs m | 51,653 | 10,975 | 470.6% | |
| Net working cap to sales | % | -1.7 | 33.9 | -4.9% | |
| Current ratio | x | 1.0 | 2.2 | 45.0% | |
| Inventory Days | Days | 92 | 104 | 88.7% | |
| Debtors Days | Days | 68 | 66 | 103.6% | |
| Net fixed assets | Rs m | 83,648 | 20,368 | 410.7% | |
| Share capital | Rs m | 846 | 253 | 334.9% | |
| "Free" reserves | Rs m | 46,397 | 30,971 | 149.8% | |
| Net worth | Rs m | 47,244 | 31,224 | 151.3% | |
| Long term debt | Rs m | 39,129 | 1,409 | 2,778.1% | |
| Total assets | Rs m | 141,209 | 45,507 | 310.3% | |
| Interest coverage | x | 2.8 | 30.0 | 9.4% | |
| Debt to equity ratio | x | 0.8 | 0 | 1,836.1% | |
| Sales to assets ratio | x | 0.5 | 0.8 | 65.5% | |
| Return on assets | % | 6.7 | 10.1 | 65.7% | |
| Return on equity | % | 9.2 | 14.2 | 65.2% | |
| Return on capital | % | 12.3 | 17.3 | 71.2% | |
| Exports to sales | % | 0 | 45.9 | 0.0% | |
| Imports to sales | % | 0 | 16.6 | 0.0% | |
| Exports (fob) | Rs m | NA | 17,308 | 0.0% | |
| Imports (cif) | Rs m | NA | 6,266 | 0.0% | |
| Fx inflow | Rs m | 22,103 | 17,308 | 127.7% | |
| Fx outflow | Rs m | 5,522 | 6,266 | 88.1% | |
| Net fx | Rs m | 16,581 | 11,042 | 150.2% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 17,981 | 4,923 | 365.3% | |
| From Investments | Rs m | -2,413 | -1,563 | 154.4% | |
| From Financial Activity | Rs m | -13,145 | -1,832 | 717.5% | |
| Net Cashflow | Rs m | 2,380 | 1,528 | 155.8% | |
Share Holding
| Indian Promoters | % | 71.5 | 45.9 | 155.8% | |
| Foreign collaborators | % | 0.0 | 0.0 | - | |
| Indian inst/Mut Fund | % | 7.0 | 11.4 | 61.6% | |
| FIIs | % | 12.6 | 25.3 | 49.8% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 8.8 | 17.4 | 50.6% | |
| Shareholders | 26,511 | 36,892 | 71.9% | ||
| Pledged promoter(s) holding | % | 0.0 | 2.1 | - |
Compare TORRENT PHARMA With: WYETH PFIZER ALEMBIC PHARMA SHASUN PHARMA SANOFI INDIA
Compare TORRENT PHARMA With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Today's Market
A Time Correction in the Nifty(Momentum Moves)
The week belonged to the bulls after bears ended the party in February. March started with gains for the bulls but historically, March has been a bears' month.
Related Views on News
IPCA LABS Announces Quarterly Results (3QFY21); Net Profit Up 32.2% (Quarterly Result Update)
Feb 5, 2021 | Updated on Feb 5, 2021For the quarter ended December 2020, IPCA LABS has posted a net profit of Rs 3 bn (up 32.2% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
TORRENT PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 27.0% (Quarterly Result Update)
Oct 27, 2020 | Updated on Oct 27, 2020For the quarter ended September 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 27.0% YoY). Sales on the other hand came in at Rs 20 bn (up 0.6% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.
IPCA LABS Announces Quarterly Results (1QFY21); Net Profit Up 243.5% (Quarterly Result Update)
Sep 29, 2020 | Updated on Sep 29, 2020For the quarter ended June 2020, IPCA LABS has posted a net profit of Rs 5 bn (up 243.5% YoY). Sales on the other hand came in at Rs 15 bn (up 46.9% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
TORRENT PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 48.6% (Quarterly Result Update)
Jul 31, 2020 | Updated on Jul 31, 2020For the quarter ended June 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 48.6% YoY). Sales on the other hand came in at Rs 21 bn (up 1.7% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.
IPCA LABS Announces Quarterly Results (3QFY20); Net Profit Up 22.8% (Quarterly Result Update)
Feb 17, 2020 | Updated on Feb 17, 2020For the quarter ended December 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 22.8% YoY). Sales on the other hand came in at Rs 11 bn (up 20.2% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
More Views on NewsMost Popular
It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)
Feb 24, 2021Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)
Feb 25, 2021In this video, I'll show you how to get started on the path to daily trading profits.
The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)
Feb 23, 2021An Indian company founded three decades ago in a garage caught my attention...
Gold 65,000 and Silver 84,000 in 2022
Feb 26, 2021In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.
MoreOUR TOP 5 IDEAS
- Free Report: Multibagger Stock Ideas 2021
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
TORRENT PHARMA SHARE PRICE
Mar 5, 2021 (Close)
TRACK TORRENT PHARMA
- Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON TORRENT PHARMA
TORRENT PHARMA 8-QTR ANALYSIS
COMPARE TORRENT PHARMA WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Warren Buffett - The Value Investor
- The Best Small-cap Stocks to Buy
- The Best Bluechip Stocks to Buy
- Your Ultimate Guide to Penny Stock Investing
- 10 Rules for Successful Long-Term Investing
- How to Invest in the Share Market
- Momentum Moves
FOLLOW
APP
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.